Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. logo
AXSM

Axsome Therapeutics, Inc. (AXSM)

$72.292.05%

Market is closed
– opens on 8 PM, 01 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$69.2649
Day's Range
$73.9352
$20.63
52-Week Range
$79.68
1 month return47.92%
3 month return15.5%
1 year return118.0%
5 year return1270.43%

Company Information

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome's core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and as a treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA.
OrganizationAxsome Therapeutics, Inc.
Employees352
CEODr. Herriot Tabuteau M.D.
IndustryHealth Technology

Analyst Recommendation

based on 15 analysts ratings

Buy
80%
Buy
13%
Hold
6%
Sell

Based on 15 Wall street analysts offering stock ratings for Axsome Therapeutics, Inc.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 44.85%

Current

$72.29

Target

$104.71

Recommendation Trend

Based on 15 analyst

Current1M Ago3M Ago
Buy
12
17
17
Hold
2
2
2
Sell
1
1
1
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
3.1B
Book Value
$3.62
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.72
PEG Ratio
0.0
Wall Street Target Price
104.71

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
15.68
Enterprise Value
2.3B
Enterprise Value/Revenue
90.95
Enterprise Value/Ebitda
-15.7

Technicals

Beta
1.75
50 Day MA
50.57
200 Day MA
41.53

Institutional Holdings

Vanguard Group Inc

7.17%

Fairmount Funds Management LLC

4.37%

RTW INVESTMENTS, LLC

3.73%

Avidity Partners Management LP

3.54%

Partner Fund Management LP

3.13%

Alethea Capital Management, LLC

1.82%

Discover more

Frequently Asked Questions

What is Axsome Therapeutics, Inc. share price today?

Can Indians buy Axsome Therapeutics, Inc. shares?

How can I buy Axsome Therapeutics, Inc. shares from India?

Can Fractional shares of Axsome Therapeutics, Inc. be purchased?

What are the documents required to start investing in Axsome Therapeutics, Inc. stocks?

What are today’s High and Low prices of Axsome Therapeutics, Inc.?

What are today’s traded volumes of Axsome Therapeutics, Inc.?

What is today’s market capitalisation of Axsome Therapeutics, Inc.?

What is the 52 Week High and Low Range of Axsome Therapeutics, Inc.?

How much percentage Axsome Therapeutics, Inc. is down from its 52 Week High?

How much percentage Axsome Therapeutics, Inc. is up from its 52 Week low?

What are the historical returns of Axsome Therapeutics, Inc.?

Who is the Chief Executive Officer (CEO) of Axsome Therapeutics, Inc.?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*